


# One year mepolizumab outcomes in severe, uncontrolled CRSwNP

## Population



CRSwNP treated with  
mepolizumab over 12 months  
n=50

## Mepolizumab



## Mepolizumab treatment




One administration every 4 weeks

BL > 1M > 3M > 6M > 9M > 12M

Follow-up time point


## SNOT 22




## NPS




## VAS SMELL




## VAS NASAL OBSTRUCTION



## EOSINOPHILIC BLOOD COUNT



## ACT score



Mepolizumab reduces polyp size, improves QoL and asthma control,  
and reduces eosinophil count after 12 months